Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target Published first ...

Detailed price information for Skye Bioscience Inc (SKYE-Q) from The Globe and Mail including charting and trades.

Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...

Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...

Get the latest Skye Bioscience Inc. R (09R.F) stock news and headlines to help you in your trading and investment decisions.

Reiterate top-line data readout from CBeyond Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye's CBeyondTM Phase 2a obesity trial extension study initiated Independen ...

Skye Bioscience is currently conducting a Phase 2a clinical trial in obesity for nimacimab, which is a negative allosteric modulating antibody that peripherally inhibits CB1.

Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...

About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors.

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and ...

On Monday, Oppenheimer maintained an Outperform rating on Skye Bioscience (NASDAQ: SKYE) but reduced the price target from $21.00 to $17.00.